SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
VRS-859 is a recombinant fusion protein containing exenatide and XTEN™, a novel hydrophilic amino acid sequence that prolongs the half life of proteins and peptides. New therapeutic compounds using the XTEN technology are expected to provide enhanced stability and less frequent dosing requirements with potentially fewer patient side effects.
“Versartis selected SynCo because of its extensive pharmaceutical manufacturing experience and its ability to deliver bulk and final product for clinical trials and ultimately, for commercialization,” said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. “We expect SynCo to ensure our goal of initiating Phase 1 clinical trials for VRS-859 in the first half of 2010. SynCo will also become our preferred manufacturing partner for future Versartis products based on the XTEN technology, which have similar production processes.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.